PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of oncotargetLink to Publisher's site
 
Oncotarget. 2016 September 13; 7(37): 60290–60302.
Published online 2016 August 11. doi:  10.18632/oncotarget.11200
PMCID: PMC5312384

Overexpression of KLF4 promotes cell senescence through microRNA-203-survivin-p21 pathway

Abstract

Krüppel-like factor 4 (KLF4) is a transcription factor and functions as a tumor suppressor or tumor promoter in different cancer types. KLF4 regulates many gene expression, thus affects the process of cell proliferation, differentiation, and apoptosis. Recently, KLF4 was reported to induce senescence during the generation of induced pluripotent stem (iPS) cells, but the exact mechanism is still unclear. In this study, we constructed two doxycycline-inducing KLF4 cell models, and demonstrated overexpression of KLF4 could promote cell senescence, detected by senescence-associated β-galactosidase activity assay. Then we confirmed that p21, a key effector of senescence, was directly induced by KLF4. KLF4 could also inhibit survivin, which could indirectly induce p21. By miRNA microarray, we found a series of miRNAs regulated by KLF4 and involved in senescence. We demonstrated that KLF4 could upregulate miR-203, and miR-203 contributed to senescence through miR-203-survivin-p21 pathway. Our results suggest that KLF4 could promote cell senescence through a complex network: miR-203, survivin, and p21, which were all regulated by overexpression of KLF4 and contributed to cell senescence.

Keywords: KLF4, p21, survivin, miR-203, senescence

INTRODUCTION

Krüppel-like factor 4 (KLF4/GKLF/EZF) is a zinc finger transcription factor that belongs to KLF transcription factor family. KLF4 functions as a context-dependent oncogene and tumor suppressor gene [1, 2]. KLF4 was reported downregulated in esophageal cancer, gastric cancer, colon cancer, kidney cancer, liver cancer and bladder cancer [38], but overexpressed in breast cancer [9, 10]. Moreover, clinical evidences indicated that inactivation of KLF4 was also associated with cancer progression and poor prognosis in some type of cancers [11, 12].

As a transcriptional factor, KLF4 can activate or repress gene expression through directly binding on promoter regions. For example, KLF4 could activate expression of p21 (also known as CIP1 and WAF1) [13], while repress the expression of Cyclin E [14]. KLF4 is involved in regulation of cell proliferation, differentiation and apoptosis [1517]. Overexpression of KLF4 inhibits cell proliferation in cell lines and suppresses carcinogenesis and tumor metastasis in mice model [6]. On the contrary, deletion of KLF4 in mice model promotes carcinogenesis in many types of cancers [18, 19].

During the process of induced pluripotent stem cells, overexpression of KLF4 could induce cell senescence in fibroblast cells. And the reprogramming-induced senescence (RIS) was thought to be an important factor and a huge barrier, which resulted in low efficiency for generation of iPS cells [2022]. On the other hand, Liu, et.al reported that in KLF4 gene knockout mice model, Klf4−/− MEFs (mouse embryonic fibroblasts) could enter senescence earlier than Klf4−/− MEFs [23].

Cellular senescence refers to the state of stable, irreversible growth arrest of a cell, always through p53/p21 and/or p16/Rb pathways [24]. Cell senescence has been regarded as a barrier of carcinogenesis in vivo, acting as an important tumor suppressor. However, recent studies revealed that although cell senescence initially functioned as a tumor suppressive factor, it might eventually exhibit some tumor-promoting effects [25].

Although oncogene-induced senescence has been intensively investigated for many years, but, whether and how tumor suppressor gene, such as KLF4, induces cell senescence is not fully explored yet. Here, we try to investigate KLF4 induced senescence in cancer cells and further decipher the molecular mechanisms of the KLF4-induced senescence.

RESULTS

KLF4 overexpression induces cellular senescence in vitro

To investigate the role of KLF4 in cell senescence, we constructed two stable cell lines, T-REx-293 KLF4 and T-REx-HeLa KLF4. As shown in Figure Figure1A,1A, KLF4 expression could be induced by 2 μg/ml doxycycline in both cell lines. KLF4 overexpression significantly suppressed cell growth (Figure (Figure1B1B and and1C).1C). In T-REx-293 KLF4 cells, KLF4 overexpression could suppress the colony formation (Figure (Figure1D).1D). DNA synthesis, measured by BrdU incorporation assay, was inhibited about 84 percent by induction of KLF4 for 5 days (Figure (Figure1E).1E). The percentage of apoptosis cells only increased from 0.93% to about 9.81% (Figure (Figure1F).1F). Then we characterized senescence in KLF4 overexpressed cells. Senescence-associated β-galactosidase activity (SA-β-gal) markedly increased in cells with KLF4 overexpression (Figure (Figure1G).1G). Transient overexpression of KLF4 could also induce cellular senescence in T-REx-293, AGS, and SW480 cells (Figure S1). We also detected the senescence related proteins by Western Blot, and found that p21WAF1/CIP1 protein was strongly accumulated after KLF4 overexpression, accompanied by reduced expression of Cyclin E1 and increased expression of Suv39H1 [26], but no significant variation of p53 and p16Ink4a (Figure (Figure1H).1H). Our data suggest that KLF4 could induce cell senescence. K409Q mutation of KLF4 might not affect the function of KLF4 in inducing senescence. (Figure S2).

Figure 1
Overexpression of KLF4 induced cellular senescence in epithelial cells

KLF4 induces senescence though directly regulating p21 transcription

KLF4 has been reported to activate p21(WAF1/Cip1) through a specific Sp1-like cis-element in p21(WAF1/Cip1) proximal promoter [13]. We found that p21 mRNA level was induced by KLF4 overexpression (Figure (Figure2A),2A), and KLF4 could bind to the promoter region of p21 gene, confirmed by ChIP assay (Figure (Figure2B).2B). We further transfected p21 siRNA plasmids (shp21) into T-REx-293 KLF4 cells. When p21 protein was knocked down (Figure (Figure2C),2C), KLF4 induction could induce only about 8 percent of senescent cells, comparing with more than 70% senescent cells in control cells (Figure (Figure2D).2D). Our results suggest that increased expression of p21, directly regulated by KLF4, is essential to KLF4 induced senescence.

Figure 2
p21 expression increased in KLF4-induced senescence

KLF4 induces senescence though survivin-p21 pathway

Our previous study showed survivin could be directly downregulated by KLF4 [27]. In camptothecin treated H1299 cells, Survivin expression is sustained during DNA damage, and reaches a nadir during senescence [28]. So we tried to test whether survivin was involved in KLF4-induced cellular senescence. Protein level of survivin (Figure (Figure3A)3A) and mRNA expression (Figure (Figure3B)3B) were both inhibited by KLF4 overexpression. Then, we overexpressed survivin in T-REx-293 KLF4 cells (Figure (Figure3C),3C), and overexpression of survivin could partially recover cell senescence induced by KLF4 (Figure (Figure3D).3D). Additionally, p21 upregulation induced by KLF4 was significantly inhibited (Figure (Figure3E).3E). It has been reported that survivin could inhibit p21 expression at transcription level by directly binding to two p53 binding sites in p21 gene promoter region [29]. In our study, survivin protein could directly bind to the distal and proximal p53 binding sites of p21 promoter in T-REx-293 KLF4 cells, as confirmed by ChIP assay (Figure (Figure3F).3F). T-REx-293 cells were co-transfected with survivin and reporter plasmids (pGL3 p21 5′, pGL3 p21 3′ or pGL3 Basic), and reporter assay showed that the transcription activities of both pGL3 p21 5′, pGL3 p21 3′ were significantly inhibited by survivin (Figure (Figure3G).3G). Our data show that survivin-p21 pathway might contribute to KLF4-induced senescence.

Figure 3
Survivin was involved in KLF4-induced senescence

KLF4 induces senescence though miR-203-survivin-p21 pathway

Regulation of miRNA expression has been reported in cell senescence [30, 31]. Here, microRNAs were evaluated with real-time PCR and microRNA array for T-REx-293 KLF4 cells. Upon KLF4 induction, thirty-two miRNAs were upregulated while eight downregulated above five folds according to Applied Biosystems microRNA array data (Table (Table1).1). miR-203 has been reported to target survivin [32, 33], and also induce senescence in human melanoma cells [34]. Then we confirmed by real-time PCR that miR-203 was up-regulated about 52 fold after KLF4 induction inT-Rex-293 KLF4 cells (Figure (Figure4A).4A). Moreover we found eight putative binding sites, matching the consensus DNA binding sequence of KLF4, 5′-(G/A)(G/A)GG(C/T)G (C/T)-3′ [35], within 2000bp upstream of miR-203 gene (Figure S3). ChIP assay showed that KLF4 could directly bind to -189bp to +11bp fragment of miR-203 gene (Figure (Figure4B).4B). To test whether miR-203 can target survivin or not, pre-miR-203 precursor and miR-203 inhibitor were transfected into T-REx-293 cells, respectively (Figure (Figure4C).4C). As shown in Figure Figure4D,4D, mRNA expression of survivin was inhibited by pre-miR-203, while inhibition of miR-203 could increase survivin expression, the similar result was shown in protein level (Figure (Figure4E).4E). To further explore the role of miR-203 in KLF4-induced senescence, miR-203 inhibitor was transfected into T-REx-293 cells for 24h. miR-203 upregulation by KLF4 was inhibited (Figure (Figure4F).4F). The inhibition of survivin was partially recovered in both mRNA and protein level (Figure (Figure4G4G and and4H).4H). p21 was reduced (Figure (Figure4H),4H), and senescence-associated β-galactosidase activity (SA-β-gal) positive cells decreased in cells pretreated with miR-203 inhibitor (Figure (Figure4I).4I). A similar result was also detected in T-REx-HeLa cell line (Figure S4). Moreover, miR-203 overexpression could induce cellular senescence in AGS and SW480 cells, and reduced survivin mRNA and protein expression were also detected in these cells (Figure S5). Our data demonstrate that miR-203-survivin-p21 pathway may be responsible for KLF4-induced senescence.

Table 1
MicroRNAs that changed more than 5 fold upon KLF4 induction of T-REx-293 KLF4 cells
Figure 4
Mir-203 could directly be upregulated by KLF4 and inhibit survivin expression

KLF4 expression predicts better prognosis in ESCC & CRC

To evaluate the potentially clinical indication of KLF4 expression, we detected KLF4 expression in esophagectomy specimens of 38 ESCC samples by immunohistochemistry and analyzed relationship between the expression of KLF4 and survival time of ESCC patients. The staining of KLF4 was intensely at cell nucleus and cytosol in normal squamous epithelium of esophagus (a, b), representative expressions of KLF4 in ESCC were shown in (c–f) (Figure (Figure5A)5A) Then, we analyzed the relation between KLF4 expression and disease-free survival of the 38 patients. Remarkably KLF4 expression level was significantly correlated with the disease-free survival of ESCC patients after surgery following with Kaplan-Meier analysis (p = 0.023) (Figure (Figure5B).5B). The median recurrence time was 12 months in low KLF4 expression group and 33 months in high expression group. Furthermore, we found similar connection between KLF4 mRNA expression and disease-free survival time of CRC patients in the openly existing GEO database (GSE24551, http://www.ncbi.nlm.nih.gov/geo/). Of 320 CRC patients, we divided them into two groups based on the median value of KLF4 expression, and found KLF4 expression levels were also significantly correlated with the disease-free survival of the CRC patients (p = 0.026) (Figure (Figure5C).5C). Moreover, KLF4 was positively correlated with Suv39H1, a senescence maker (Figure (Figure5D).5D). The result implied that KLF4 overexpression might induce senescence and predicted better prognosis in cancer patients.

Figure 5
KLF4 expression predicted better prognosis of ESCC and CRC patients

DISCUSSION

KLF4 could induce cell senescence during the process of induced pluripotent stem cells in fibroblast cells [22]. Here by constructing a cell model of doxycycline inducing KLF4 expression in T-REx-293 cells, we tried to investigate how KLF4 induced cell senescence. In our study, overexpression of KLF4 could indeed promote cellular senescence in T-REx-293 and other cell lines. It seems that increased expression of p21 by KLF4 is likely the main pathway for KLF4 induced senescence in this system. However, it was recently reported that KLF4 deficiency caused premature senescence in mouse embryonic fibroblasts by inducing oxidative DNA damage and activating p53/p21 pathway [23]. As an important transcription factor, while overexpression of KLF4 could directly induce p21 and senescence, knockout of KLF4 may also activate upstream of p53 and induce p53/p21 pathway. Except for KLF4, there are also several other genes which could induce senescence whether overexpression or inhibition, such as PTTG [36], and c-Myc [37].

Recently it was reported that KLF4 K409Q together with TRAF7 mutations were harbored in most secretory meningioma patients [39]. This scenario was confirmed by the others [40]. Since residue K409 is located within the first zinc finger and direct DNA binding motif of KLF4, it implies that the K409Q mutation might destroy the binding between KLF4 and DNA. However, according to our results, sole KLF4 409Q mutation had no significant effect on both p21 expression and senescence in HEK293 and HeLa cells. There were several reports about KLF4 mediated the transactivation of p53 on p21 promoter [13, 41]. In our study, KLF4 could induce p21 expression without affecting p53 expression. Even in HeLa cells in which p53 should be functionally suppressed by HPV [42], KLF4 could still induce cellular senescence. Besides, KLF4 could also induce senescence in human colon cancer cell line HCT116 (p53 −/−) (data not shown). But when we knocked down p21, the senescence percentage was significantly reduced. It was reported that p21 loss could even convert KLF4 from cell-cycle inhibitor into oncoprotein [1]. So p21 seems to be the essential target of KLF4 during cellular senescence in our system.

Survivin is one of KLF4′s target genes [27]. Survivin involves in several disparate molecular networks of cellular division, intracellular signaling, and apoptosis [43, 44]. Survivin was reported to be downregulated during drug induced senescence, and to be overexpressed in cells escaping from senescence [28]. It was also reported that senescence was a reversible process controlled by survivin, so that overexpression of survivin in senescent cancer stem cells could promote tumorigenesis [45]. Inhibition of survivin usually correlated with upregulation of p21, especially during senescence [46, 47]. Our results showed that KLF4 inhibited expression of survivin and p21 was upregualted. Moreover, we proposed that direct binding of survivin protein to p21 promoter region might be involved in the senescent process. Although survivin is not a classical transcription factor, it could bind to two p53 binding sites of p21 gene promoter, inhibiting p21 expression [29].

KLF4 has been reported to regulate microRNA expression, such as miR-206, and miR-146a [48, 49]. In our system, we find some microRNAs as potential targets of KLF4. Some of these microRNAs could induce senescence, such as miR-203 [34], miR-141, and miR-22 [50, 51]. Among them, miR-203 can target survivin [32]. In our study, we confirmed miR-203 inhibited survivin expression, and KLF4 could induce miR-203 expression. Combining with our previous data that KLF4 directly inhibited survivin expression [32], our results demonstrate that KLF4 could regulate survivin through direct or indirect manner during inducing cell senescence.

As a tumor suppressor gene, KLF4 was downregulated in cancer tissues compared with noncancerous tissues in gastrointestinal track [52]. Decreased KLF4 expression highly related to a poor survival in gastric cancer and colon cancer [52, 53]. In our study, we found that KLF4 expression significantly related to disease-free survival of ESCC patients, and high expression of KLF4 showed a better disease-free survival. Besides, using GEO databases, we found that KLF4 mRNA expression also correlated with disease-free survival of CRC patients, which further confirmed our hypothesis. Cellular senescence is usually thought to be a barrier of tumor initiation and development. Then it is reasonable to speculate that the senescent cells in cancer tissue may predict a better survival time of cancer patients. Except for KLF4, overexpression of DEC1, p21 and ING1, which could induce cell senescence, are associated with a better survival in certain cancers, indicating that senescence may also have a protective function in cancer development [5457]. Although more evidence of how KLF4 induce senescence in vivo is needed, our results strongly implied that KLF4 might resist cancer progression through promoting cellular senescence.

Taken together, our study described a model that KLF4 could induce senescence through a complex regulatory network: direct induction of p21, inhibition of survivin that indirectly induced p21, and induction of miR-203, which targeted survivin and induced p21 expression (Figure (Figure6).6). Moreover, overexpression of KLF4 is significantly consistent with better prognosis in ESCC and CRC patients. Our data shed light on the function of KLF4 of inducing cellular senescence in vitro and preventing tumor progression in vivo.

Figure 6
The signaling network of KLF4-inducing senescence

MATERIALS AND METHODS

Plasmids, pre-miR precursors and antisense oligonucleotides

pcDNA4 HA-KLF4 was generated from double digestion of pcDNA3 HA-KLF4 [27], followed by ligation to pcDNA4™/TO/myc-His B (Invitrogen, Carlsbad, CA). pcDNA4 HA-KLF4-K409Q plamids was further constructed containing 1225 A to C mutation. Survivin expression plasmid pcDNA3.0 survivin, pGL3 p21 5′, pGL3 p21 3′ and p21 shRNA plasmids pSilencer3.0 shp21 were constructed as described previously [58, 59]. The pre-miR-203 precursor, pre-miR negative control, miR-203 inhibitor and scrambled oligonucleotides of miR-203 were purchased from Ambion (Austin, TX, USA).

Cell lines and transfection

T-REx™-293 and T-REx™- HeLa were cultured in DMEM (Gibco). All medium contained 10% fetal bovine serum and supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin. Cells were maintained at 37°C in a humidified incubator with 5% CO. Lipofectamine2000 (Invitrogen) was used for plasmids and oligonucleotides transfection; siPORT NeoFX transfection agent (Ambion) was used for pre-miR-203 precursor, miR-203 inhibitor, scrambled oligonucleotides (Ambion) transfection, according to the manufacturer's instructions.

For the establishment of stable transfected cell lines, cells were selected with Zeocin (100 μg/ml, Invitrogen) after transfection. 2 μg/ml doxycycline (Sigma Aldrich) was used to induce KLF4 over-expression. The resistant cell lines were designated as T-REx-293 KLF4, T-REx-293 PC4, T-REx-HeLa KLF4 and T-REx-HeLa PC4, respectively.

Protein preparation and Western blotting

Cells were harvested and lysed in RIPA buffer (Sigma Aldrich) and protein concentrations were measured by a BCA protein detection kit (Pierce, Rockford, IL, USA). Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. Primary antibodies against KLF4 (1:1000, Santa Cruz), β-actin (1:5000, Sigma Aldrich), p21 (1:1000, Cell Signaling), HA-Tag (1:1000, Santa Cruz), Cyclin E1(1:1000, Abcam), p53 (1:1000, DAKO), p16 (1:1000, Santa Cruz), Suv39H1 (1:1000, Santa Cruz), survivin (1:1000, Abcam) and horseradish peroxidase conjugated secondary antibodies (Zhongshan, Beijing, China) were used to detect specific proteins according to the standard procedures. Finally, the membranes developed with a Luminol Detection System (Santa Cruz). Protein expression was quantified using a Gel EDAS 290 analysis system (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA) and Gel-Pro Analyzer 3.1 software (Media Cybernetics, Silver Spring, MD, USA).

Senescence-associated β-galactosidase (SA-β-Gal) staining assay

Cultured cells were seeded in 6-well plates and either transfected with intented plasmids, pre-miR precursors, antisense oligonucleotides, or treated with 2 μg/ml doxycycline. After 72 h, the cells were stained with Senescence Cells Histochemical Staining Kit (Sigma) according to the manufacturer's procedure.

Cell growth and MTT assay

T-REx-293 KLF4, T-REx-293 PC4 cells were plated into 24-well plates at a density of 50 cells/mm2 in triplicate with or without 2 μg/ml doxycycline. Cells were harvested every day and cell numbers were counted. For MTT assay, 2,000 T-REx-293 KLF4, T-REx-293 PC4 cells were seeded into 96-well plates and with or without 2 μg/ml doxycycline treatment for 1 to 6 days. Then, 20 μl 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (5 mg/mL) was added to each test well, and incubated for 4 h at 37°C. The supernatant was discarded and 150 μl dimethyl sulfoxide (DMSO) was added to each well to solubilize the crystals for 10 min at room temperature and measured at a wavelength of 570 nm with the model 680 microplate reader (Bio-Rad, Hercules, CA, USA).

Colony formation assay

T-REx-293 KLF4 cells were seeded into 10 cm cell culture dishes of 2000 cells/well in triplicate with or without 2 μg/ml doxycycline. After about two weeks, obvious clones in control wells could be observed, and then cells were washed with PBS and fixed with formaldehyde. Then the cells were stained with Giemsa staining solution and clones were counted.

BrdU incorporation assay

BrdU Cell Proliferation Assay (Calbiochem, San Diego, CA, USA) kit was used to detect newly synthesized DNA in vitro, T-REx-293 KLF4 cells in a 96 well cell culture plate (5,000 cells per well) were treated with 2 μg/ml doxycycline for 0 to 5 days, and then incubated with medium containing BruU for 6 h and processed according to the instructions of the manufacturer. The signal was detected using a model 680 microplate reader (Bio-Rad) at dual wavelengths of 450/570 nm.

Total RNA preparation

Total RNA was prepared using Trizol Reagent (Ambion) in accordance with the manufacturer's protocol. Concentration was measured by NanoDrop 2000 (NanoDrop, Wilmington, DE, USA).

TaqMan Real-time PCR microRNA array

T-REx-293 KLF4 cells with or without 2 μg/ml doxycycline treatment for three days were harvested and washed in cold sterile phosphate buffered saline (PBS), and then miRNA was isolated using a mirVana RNA isolation kit (Ambion). The stem-loop RT-PCR based TaqMan MicroRNA Arrays (Applied Biosystems, Foster City, CA, USA) representing the 663 mature miRNAs in a two-card set of arrays (Array A and B) were used. RT-PCR reactions were performed according to the manufacturer's instructions. All reagents were obtained from Applied Biosystems. The quantitative miRNA expression data were acquired using the ABI 7900HT SDS software (Applied Biosystems). The Ct value of an endogenous control gene (Mamm U6) was subtracted from the corresponding Ct value of the target gene resulting in the Ct value which was used for relative quantification of miRNA expression. The clustering analysis was performed using a hierarchical method and average linkage [60]. The fold changes in gene expression were calculated using the 2−ΔΔct method [61].

Real-time PCR

Total RNA was prepared using Trizol Reagent (Ambion) in accordance with the manufacturer's protocol. Concentration and purity of total RNA samples were measured by NanoDrop 2000 (NanoDrop). Total RNA was reverse-transcribed to cDNA with M-MLV reverse transcriptase (Promega, Fitchburg, WI, USA), according to the manufacturer's instructions. Power SYBR Green Master Mix (Applied Biosystems) was used for real-time PCR applications. β-actin was used to normalize data. Sequences of the PCR primers were as follows: p21 forward: 5′- GGCTCCTTCCCATCGCTGTCA -3′, and reverse: 5′-GTCACCCTGCCCAACCTTAGA-3′; survivin forward: 5′-AGGACCACCGCATCTCTACAT-3′, and reverse: 5′-AAGTCTGGCTCGTTCTCAGTG-3′; β-actin forward: 5′-GGCGGCACCACCATGTACCCT-3′, and reverse: 5′-AGGGGCCGGACTCGTCATACT-3′.

For miRNA analysis, reverse transcription and stem-loop real-time RT-PCR were performed as described [62] using TaqMan MicroRNA individual assays, TaqMan MicroRNA Reverse Transcription kit, and TaqMan Universal PCR master mix without AmpErase UNG (Applied Biosystems). For normalization, U6 small nuclear RNA was used as control. The quantitative real-time PCR of each sample was performed in triplicate on an Step One Plus Real-Time PCR Systems (Applied Biosystems) according to the manufacturer's protocol.

Chromatin immunoprecipitation (ChIP) assay

ChIP assay was conducted with the ChIP-IT Express kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer's protocol. The antibodies for immunoprecipitation include an anti-KLF4 (Santa Cruz), anti-survivin (Abcam) antibodies. PCR was performed with primers amplifying intended promoter regions. Primers specific for putative KLF4 binding sites and survivin binding sites upstream of p21 promoter were reported previously [29, 63].

PCR primers used for KLF4 binding sites to microRNA-203 promoter were: forward: 5′-ATCCCCC AGCGCCAGGCGAG-3′, and reverse: 5′-GTCCCCAA CACCGTCGGTTC-3′. ChIP experiments were repeated at least three times and representative results were shown.

Tissue sample collection and immunohistochemistry

Esophageal squamous cell carcinoma (ESCC) tissues from 38 patients who had received esophagectomy were collected in Cancer Hospital, Chinese Academy of Medical Science from December, 2000 to June, 2001. The follow-up period was from 3 months to 92 months, with a mean period of 39.6 months. The disease-free survival time was defined as the time between diagnosis of esophageal squamous cell carcinoma and recurrence of disease. The study was approved by the medical ethics committee of Cancer Hospital, Chinese Academy of Medical Science.

Slides were probed with anti-KLF4 antibody (1:100, Santa Cruz) and assessed by two individual investigators. KLF4 immunoreactivity was scored 0~3 by the color and percentage of cells showing distinct nuclear and/or diffuse cytoplasmic immunohistochemical reaction. Scores of 0~1 were defined as “low expression”, and scores of 2~3 as “high expression”.

Statistical Analysis

Statistical analysis was performed using SPSS 18.0 software (SPSS, Chicago, IL, USA). Data were presented as mean ± s.d of at least three independent experiments. Differences between the two groups were examined by Student's two-tailed non-paired t-test and a nonparametric test (Mann-Whitney U-test for two groups). Survival analysis was carried out using Kaplan-Meier method with log-rank test. A p value < 0.05 was considered statistically significant.

SUPPLEMENTARY MATERIALS FIGURES

Footnotes

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

GRANT SUPPORT

This work was supported by National Natural Science Foundation (31171322, 81021061, 81321091), the National 863 High Tech Foundation (2012AA02A503) and Innovation Foundation for Doctoral Students of PUMC (2011-1001-022).

REFERENCES

1. Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nature cell biology. 2005;7:1074–1082. [PubMed]
2. Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer. 2006;6:11–23. [PubMed]
3. Yang Y, Goldstein BG, Chao HH, Katz JP. KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol Ther. 2005;4:1216–1221. [PubMed]
4. Kanai M, Wei D, Li Q, Jia Z, Ajani J, Le X, Yao J, Xie K. Loss of Kruppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin Cancer Res. 2006;12:6395–6402. [PubMed]
5. Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE, Yang VW. Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene. 2004;23:395–402. [PMC free article] [PubMed]
6. Song E, Ma X, Li H, Zhang P, Ni D, Chen W, Gao Y, Fan Y, Pang H, Shi T, Ding Q, Wang B, Zhang Y, et al. Attenuation of kruppel-like factor 4 facilitates carcinogenesis by inducing g1/s phase arrest in clear cell renal cell carcinoma. PloS One. 2013;8:e67758. [PMC free article] [PubMed]
7. Lin ZS, Chu HC, Yen YC, Lewis BC, Chen YW. Kruppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression. PLoS One. 2012;7:e43593. [PMC free article] [PubMed]
8. Ohnishi S, Ohnami S, Laub F, Aoki K, Suzuki K, Kanai Y, Haga K, Asaka M, Ramirez F, Yoshida T. Downregulation and growth inhibitory effect of epithelial-type Kruppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem Biophys Res Commun. 2003;308:251–256. [PubMed]
9. Foster KW, Frost AR, McKie-Bell P, Lin CY, Engler JA, Grizzle WE, Ruppert JM. Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res. 2000;60:6488–6495. [PubMed]
10. Yu F, Li J, Chen H, Fu J, Ray S, Huang S, Zheng H, Ai W. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene. 2011;30:2161–2172. [PMC free article] [PubMed]
11. Li H, Wang J, Xiao W, Xia D, Lang B, Wang T, Guo X, Hu Z, Ye Z, Xu H. Epigenetic inactivation of KLF4 is associated with urothelial cancer progression and early recurrence. The Journal of urology. 2014;191:493–501. [PubMed]
12. Liu Z, Yang H, Luo W, Jiang Q, Mai C, Chen Y, Zhen Y, Yu X, Long X, Fang W. Loss of cytoplasmic KLF4 expression is correlated with the progression and poor prognosis of nasopharyngeal carcinoma. Histopathology. 2013;63:362–370. [PubMed]
13. Zhang W, Geiman DE, Shields JM, Dang DT, Mahatan CS, Kaestner KH, Biggs JR, Kraft AS, Yang VW. The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. J Biol Chem. 2000;275:18391–18398. [PMC free article] [PubMed]
14. Yoon HS, Ghaleb AM, Nandan MO, Hisamuddin IM, Dalton WB, Yang VW. Kruppel-like factor 4 prevents centrosome amplification following gamma-irradiation-induced DNA damage. Oncogene. 2005;24:4017–4025. [PMC free article] [PubMed]
15. Chen X, Johns DC, Geiman DE, Marban E, Dang DT, Hamlin G, Sun R, Yang VW. Kruppel-like factor 4 (gut-enriched Kruppel-like factor) inhibits cell proliferation by blocking G1/S progression of the cell cycle. J Biol Chem. 2001;276:30423–30428. [PMC free article] [PubMed]
16. Chen X, Whitney EM, Gao SY, Yang VW. Transcriptional profiling of Kruppel-like factor 4 reveals a function in cell cycle regulation and epithelial differentiation. J Mol Biol. 2003;326:665–677. [PMC free article] [PubMed]
17. Chen ZY, Shie J, Tseng C. Up-regulation of gut-enriched kruppel-like factor by interferon-gamma in human colon carcinoma cells. FEBS Lett. 2000;477:67–72. [PubMed]
18. Abrigo M, Alvarez R, Paparella ML, Calb DE, Bal de Kier Joffe E, Gutkind JS, Raimondi AR. Impairing squamous differentiation by Klf4 deletion is sufficient to initiate tongue carcinoma development upon K-Ras activation in mice. Carcinogenesis. 2014;35:662–669. [PubMed]
19. Ghaleb AM, McConnell BB, Nandan MO, Katz JP, Kaestner KH, Yang VW. Haploinsufficiency of Kruppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis. Cancer research. 2007;67:7147–7154. [PMC free article] [PubMed]
20. Li H, Collado M, Villasante A, Strati K, Ortega S, Canamero M, Blasco MA, Serrano M. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature. 2009;460:1136–1139. [PMC free article] [PubMed]
21. Gewirtz DA, Holt SE, Elmore LW. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol. 2008;76:947–957. [PubMed]
22. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, Pinho S, Silva JC, Azuara V, Walsh M, Vallier L, Gil J. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev. 2009;23:2134–2139. [PubMed]
23. Liu C, La Rosa S, Hagos EG. Oxidative DNA damage causes premature senescence in mouse embryonic fibroblasts deficient for Kruppel-like factor 4. Molecular carcinogenesis. 2015;54:889–99. [PubMed]
24. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011;192:547–556. [PMC free article] [PubMed]
25. Ohtani N, Takahashi A, Mann DJ, Hara E. Cellular senescence: a double-edged sword in the fight against cancer. Experimental dermatology. 2012;21(Suppl 1):1–4. [PubMed]
26. Dorr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Dabritz JH, Lisec J, Lenze D, Gerhardt A, Schleicher K, Kratzat S, Purfurst B, Walenta S, et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature. 2013;501:421–425. [PubMed]
27. Zhang G, Zhu H, Wang Y, Yang S, Liu M, Zhang W, Quan L, Bai J, Liu Z, Xu N. Kruppel-like factor 4 represses transcription of the survivin gene in esophageal cancer cell lines. Biological chemistry. 2009;390:463–469. [PubMed]
28. Wang Q, Wu PC, Roberson RS, Luk BV, Ivanova I, Chu E, Wu DY. Survivin and escaping in therapy-induced cellular senescence. Int J Cancer. 2011;128:1546–1558. [PMC free article] [PubMed]
29. Tang L, Ling X, Liu W, Das GM, Li F. Transcriptional inhibition of p21WAF1/CIP1 gene (CDKN1) expression by survivin is at least partially p53-dependent: evidence for survivin acting as a transcription factor or co-factor. Biochemical and biophysical research communications. 2012;421:249–254. [PMC free article] [PubMed]
30. Cho JH, Dimri M, Dimri GP. MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence. J Biol Chem. 2015;290:10555–10567. [PMC free article] [PubMed]
31. Ito T, Yagi S, Yamakuchi M. MicroRNA-34a regulation of endothelial senescence Biochem. Biophys. Res. Commun. 2010;398:735–740. [PubMed]
32. Wei W, Wanjun L, Hui S, Dongyue C, Xinjun Y, Jisheng Z. miR-203 inhibits proliferation of HCC cells by targeting survivin. Cell biochemistry and function. 2013;31:82–85. [PubMed]
33. Bian K, Fan J, Zhang X, Yang XW, Zhu HY, Wang L, Sun JY, Meng YL, Cui PC, Cheng SY, Zhang J, Zhao J, Yang AG, et al. MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS letters. 2012;586:804–809. [PubMed]
34. Noguchi S, Mori T, Otsuka Y, Yamada N, Yasui Y, Iwasaki J, Kumazaki M, Maruo K, Akao Y. Anti-oncogenic microRNA-203 induces senescence by targeting E2F3 protein in human melanoma cells. The Journal of biological chemistry. 2012;287:11769–11777. [PMC free article] [PubMed]
35. Shields JM, Yang VW. Identification of the DNA sequence that interacts with the gut-enriched Kruppel-like factor. Nucleic Acids Res. 1998;26:796–802. [PMC free article] [PubMed]
36. Chesnokova V, Melmed S. Pituitary senescence: the evolving role of Pttg. Molecular and cellular endocrinology. 2010;326:55–59. [PMC free article] [PubMed]
37. Prathapam T, Aleshin A, Guan Y, Gray JW, Martin GS. p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs. The Journal of biological chemistry. 2010;285:32529–32538. [PMC free article] [PubMed]
39. Reuss DE, Piro RM, Jones DT, Simon M, Ketter R, Kool M, Becker A, Sahm F, Pusch S, Meyer J, Hagenlocher C, Schweizer L, Capper D, et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol. 2013;125:351–358. [PubMed]
40. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegariu O, Yilmaz S, Gunel JM, Carrion-Grant G, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339:1077–1080. [PMC free article] [PubMed]
41. Yoon HS, Chen X, Yang VW. Kruppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage. J Biol Chem. 2003;278:2101–2105. [PMC free article] [PubMed]
42. Hoppe-Seyler F, Butz K. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. Journal of virology. 1993;67:3111–3117. [PMC free article] [PubMed]
43. Li F, Ling X. Survivin study: an update of “what is the next wave”? Journal of cellular physiology. 2006;208:476–486. [PMC free article] [PubMed]
44. Li F. Survivin study: what is the next wave? Journal of cellular physiology. 2003;197:8–29. [PubMed]
45. La Porta CA, Zapperi S, Sethna JP. Senescent cells in growing tumors: population dynamics and cancer stem cells. PLoS Comput Biol. 2012;8:e1002316. [PMC free article] [PubMed]
46. Al Dhaheri Y, Attoub S, Arafat K, Abuqamar S, Eid A, Al Faresi N, Iratni R. Salinomycin induces apoptosis and senescence in breast cancer: upregulation of p21, downregulation of survivin and histone H3 and H4 hyperacetylation. Biochimica et biophysica acta. 2013;1830:3121–3135. [PubMed]
47. Shi X, Wang D, Ding K, Lu Z, Jin Y, Zhang J, Pan J. GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Cancer biology & therapy. 2010;9:640–650. [PubMed]
48. Lin CC, Liu LZ, Addison JB, Wonderlin WF, Ivanov AV, Ruppert JM. A KLF4-miRNA-206 autoregulatory feedback loop can promote or inhibit protein translation depending upon cell context. Mol Cell Biol. 2011;31:2513–2527. [PMC free article] [PubMed]
49. Sun SG, Zheng B, Han M, Fang XM, Li HX, Miao SB, Su M, Han Y, Shi HJ, Wen JK. miR-146a and Kruppel-like factor 4 form a feedback loop to participate in vascular smooth muscle cell proliferation. EMBO Rep. 2011;12:56–62. [PubMed]
50. Itahana Y, Neo SH, Itahana K. miR-141, a new player, joins the senescence orchestra. Cell Cycle. 2013:12. [PMC free article] [PubMed]
51. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A, Ochiya T, Tahara H. miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol. 2011;193:409–424. [PMC free article] [PubMed]
52. Patel NV, Ghaleb AM, Nandan MO, Yang VW. Expression of the tumor suppressor Kruppel-like factor 4 as a prognostic predictor for colon cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:2631–2638. [PMC free article] [PubMed]
53. Hsu LS, Chan CP, Chen CJ, Lin SH, Lai MT, Hsu JD, Yeh KT, Soon MS. Decreased Kruppel-like factor 4 (KLF4) expression may correlate with poor survival in gastric adenocarcinoma. Med Oncol. 2013;30:632. [PubMed]
54. Viale G, Pellegrini C, Mazzarol G, Maisonneuve P, Silverman ML, Bosari S. p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations. The Journal of pathology. 1999;187:302–307. [PubMed]
55. Bose P, Thakur SS, Brockton NT, Klimowicz AC, Kornaga E, Nakoneshny SC, Riabowol KT, Dort JC. Tumor cell apoptosis mediated by cytoplasmic ING1 is associated with improved survival in oral squamous cell carcinoma patients. Oncotarget. 2014;5:3210–3219. doi: 10.18632/oncotarget.1907. [PMC free article] [PubMed] [Cross Ref]
56. Li N, Li Q, Cao X, Zhao G, Xue L, Tong T. The tumor suppressor p33ING1b upregulates p16INK4a expression and induces cellular senescence. FEBS letters. 2011;585:3106–3112. [PubMed]
57. Xu Q, Ma P, Hu C, Chen L, Xue L, Wang Z, Liu M, Zhu H, Xu N, Lu N. Overexpression of the DEC1 protein induces senescence in vitro and is related to better survival in esophageal squamous cell carcinoma. PLoS One. 2012;7:e41862. [PMC free article] [PubMed]
58. Zhu H, Liu S, Zhou C, Zhou X, Zhang F, Jin L, Xu N. Anti-apoptosis gene survivin promotes cell growth and transformation. Zhonghua yi xue za zhi. 2002;82:338–340. [PubMed]
59. Zhang J, Lou X, Yang S, He S, Yang L, Liu M, Zhu H, Shan Q, Su S, Zhan Q, Xu N, Liu S. BAG2 is a target of the c-Myc gene and is involved in cellular senescence via the p21(CIP1) pathway. Cancer Lett. 2012;318:34–41. [PubMed]
60. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863–14868. [PubMed]
61. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. [PubMed]
62. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33:e179. [PMC free article] [PubMed]
63. Ghaleb AM, Katz JP, Kaestner KH, Du JX, Yang VW. Kruppel-like factor 4 exhibits antiapoptotic activity following gamma-radiation-induced DNA damage. Oncogene. 2007;26:2365–2373. [PMC free article] [PubMed]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC